HUS1600044I1 - Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával - Google Patents

Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Info

Publication number: HUS1600044I1
Authority: HU; Hungary
Prior art keywords: antibodies; methods; multiple myeloma; combination therapies; treating multiple
Prior art date: 2006-08-07

Application number

HUS1600044C

Other languages

English (en)

Original Assignee

Abbvie Biotherapeutics Inc

Dana-Farber Cancer Institute Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-07

Filing date

2016-10-20

Publication date

2016-12-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1600044(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-20 Application filed by Abbvie Biotherapeutics Inc, Dana-Farber Cancer Institute Inc filed Critical Abbvie Biotherapeutics Inc

2016-12-28 Publication of HUS1600044I1 publication Critical patent/HUS1600044I1/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Ultra Sonic Daignosis Equipment (AREA)

HUS1600044C 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával HUS1600044I1 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83618506P	2006-08-07	2006-08-07
US94426207P	2007-06-15	2007-06-15
EP07840746.7A EP2068874B1 (en)	2006-08-07	2007-08-07	Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number	Publication Date
HUS1600044I1 true HUS1600044I1 (hu)	2016-12-28

Family

ID=38831279

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HUE13168383A HUE029027T2 (hu)	2006-08-07	2007-08-07	Eljárások myeloma multiplex kezelésére HuLuc63 és bortezomib alapú kombinációs terápiák alkalmazásával
HUS1600045C HUS1600045I1 (hu)	2006-08-07	2016-10-20	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
HUS1600044C HUS1600044I1 (hu)	2006-08-07	2016-10-20	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
HUS1600043C HUS1600043I1 (hu)	2006-08-07	2016-10-20	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
HUE13168383A HUE029027T2 (hu)	2006-08-07	2007-08-07	Eljárások myeloma multiplex kezelésére HuLuc63 és bortezomib alapú kombinációs terápiák alkalmazásával
HUS1600045C HUS1600045I1 (hu)	2006-08-07	2016-10-20	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS1600043C HUS1600043I1 (hu)	2006-08-07	2016-10-20	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Country Status (23)

Country	Link
US (4)	US8632772B2 (hu)
EP (5)	EP2641601B8 (hu)
JP (1)	JP5340935B2 (hu)
CN (1)	CN101686971B (hu)
AU (1)	AU2007281684C1 (hu)
BR (1)	BRPI0716647A2 (hu)
CA (1)	CA2660356C (hu)
CY (5)	CY1116247T1 (hu)
DK (2)	DK2641601T3 (hu)
ES (2)	ES2589302T3 (hu)
HR (2)	HRP20150449T1 (hu)
HU (4)	HUE029027T2 (hu)
IL (2)	IL196919A (hu)
LT (4)	LT2641601T (hu)
LU (3)	LU93277I2 (hu)
MX (1)	MX2009001441A (hu)
NL (1)	NL300840I2 (hu)
NO (1)	NO346835B1 (hu)
NZ (1)	NZ574978A (hu)
PL (2)	PL2641601T3 (hu)
PT (2)	PT2641601T (hu)
SI (2)	SI2068874T1 (hu)
WO (1)	WO2008019378A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8632772B2 (en)	2006-08-07	2014-01-21	Dana-Farber Cancer Institute	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
NZ574979A (en)	2006-08-07	2012-06-29	Abbott Biotherapeutics Corp	Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP3384919A1 (en)	2008-06-02	2018-10-10	Dana Farber Cancer Institute, Inc.	Cs1 peptides
AU2009271401A1 (en) *	2008-06-16	2010-01-21	Immunogen Inc.	Novel synergistic effects
US20110236428A1 (en) *	2008-10-21	2011-09-29	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
EP2476438B1 (en)	2009-09-10	2014-07-23	Kyowa Hakko Kirin Co., Ltd.	Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
CA2780998C (en) *	2009-11-24	2016-07-12	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) *	2010-05-13	2014-05-14	四川大学	抗骨髓瘤细胞多克隆抗体及其制备方法
US9950047B2 (en)	2012-11-05	2018-04-24	Dana-Farber Cancer Institute, Inc.	XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
ES2707057T3 (es)	2013-11-06	2019-04-02	Bristol Myers Squibb Co	Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
WO2015069703A1 (en)	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens and combinations thereof
SI3071597T1 (sl) *	2013-11-21	2020-11-30	F. Hoffmann-La Roche Ag	Anti alfa-sinukleinska protitelesa in postopki uporabe
US10034872B2 (en)	2014-08-22	2018-07-31	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016049022A1 (en) *	2014-09-23	2016-03-31	Board Of Trustees Of Michigan State University	Compositions and methods for modulating an immune response
US10365280B2 (en)	2014-10-02	2019-07-30	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating malignancies
JP2017537893A (ja)	2014-10-31	2017-12-21	アッヴィ・バイオセラピューティクス・インコーポレイテッド	抗ｃｓ１抗体および抗体薬結合体
US10302644B2 (en)	2014-11-04	2019-05-28	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating multiple myeloma
MX2017007097A (es)	2014-12-04	2017-09-05	Bristol Myers Squibb Co	Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
SMT202100202T1 (it)	2015-05-13	2021-05-07	Morphosys Ag	Trattamento per il mieloma multiplo
CA2990478A1 (en)	2015-06-29	2017-01-05	Bristol-Myers Squibb Company	Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN109432398A (zh) *	2016-03-13	2019-03-08	曹帅	一种用于治疗骨髓增生、骨癌的药物组合物及其用途
CN110382546B (zh) *	2017-03-29	2024-08-09	新加坡科技研究局	抗寡糖抗体
WO2019104001A1 (en) *	2017-11-22	2019-05-31	Hillstream Biopharma Inc.	Polymeric nanoparticles comprising bortezomib
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US20220390455A1 (en)	2019-11-05	2022-12-08	Bristol-Myers Squibb Company	M-protein assays and uses thereof
CN115368462B (zh) *	2022-07-19	2026-01-02	合肥天港免疫药物有限公司	双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112969A (en)	1994-03-17	2001-05-20	Baxter Int	Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
EP0831860B1 (en)	1995-05-25	2004-10-20	Baxter International Inc.	Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2272513A1 (en) *	2002-05-17	2011-01-12	Celgene Corporation	Pharmaceutical compositions for treating cancer
US7709610B2 (en) *	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) *	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
CA2595398A1 (en) *	2004-11-04	2006-05-11	Fibron Limited	Treatment of b-cell malignancies
NZ574979A (en) *	2006-08-07	2012-06-29	Abbott Biotherapeutics Corp	Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
US8632772B2 (en)	2006-08-07	2014-01-21	Dana-Farber Cancer Institute	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US20080095768A1 (en)	2006-08-07	2008-04-24	Pdl Biopharma, Inc.	Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

2007
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en not_active Ceased
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/hu unknown
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I2/el unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned

Also Published As

Publication number	Publication date
LTPA2016030I1 (lt)	2016-11-10
PT2068874E (pt)	2015-05-21
LT2641601T (lt)	2016-10-10
CA2660356A1 (en)	2008-02-14
ES2535437T3 (es)	2015-05-11
US20170342150A1 (en)	2017-11-30
EP2942057A1 (en)	2015-11-11
LTPA2016031I1 (lt)	2016-11-10
HRP20161284T1 (hr)	2016-12-16
CY2016036I1 (el)	2017-07-12
SI2068874T1 (sl)	2015-06-30
AU2007281684A1 (en)	2008-02-14
CN101686971A (zh)	2010-03-31
LTC2068874I2 (lt)	2018-11-12
HRP20150449T1 (xx)	2015-06-05
PT2641601T (pt)	2016-10-14
HUE029027T2 (hu)	2017-01-30
SI2641601T1 (sl)	2016-11-30
US20140322201A1 (en)	2014-10-30
LU93277I2 (fr)	2016-12-27
EP2068874A1 (en)	2009-06-17
IL243933A0 (en)	2016-04-21
DK2068874T3 (da)	2015-04-27
WO2008019378A1 (en)	2008-02-14
EP2641601A1 (en)	2013-09-25
EP2641600A1 (en)	2013-09-25
CA2660356C (en)	2016-04-05
IL196919A0 (en)	2009-11-18
US8632772B2 (en)	2014-01-21
LU93276I2 (fr)	2016-12-27
BRPI0716647A2 (pt)	2017-05-16
NL300840I2 (hu)	2017-01-03
EP3115049A1 (en)	2017-01-11
AU2007281684B2 (en)	2013-05-16
CY1117992T1 (el)	2017-05-17
HK1129853A1 (en)	2009-12-11
NO346835B1 (no)	2023-01-23
LU93275I2 (fr)	2016-12-27
HUS1600045I1 (hu)	2016-12-28
NZ574978A (en)	2012-08-31
PL2068874T3 (pl)	2015-06-30
MX2009001441A (es)	2009-07-06
EP2641601B8 (en)	2016-09-21
US20080152646A1 (en)	2008-06-26
CN101686971B (zh)	2013-09-11
CY2016038I1 (el)	2017-07-12
LTPA2016029I1 (lt)	2016-11-10
EP2068874B1 (en)	2015-01-28
NO20090968L (no)	2009-04-30
AU2007281684C1 (en)	2013-12-19
JP5340935B2 (ja)	2013-11-13
IL196919A (en)	2016-03-31
ES2589302T3 (es)	2016-11-11
DK2641601T3 (en)	2016-08-22
JP2010500371A (ja)	2010-01-07
CY2016037I1 (el)	2017-07-12
EP2641601B1 (en)	2016-07-06
HUS1600043I1 (hu)	2016-12-28
US20160137735A1 (en)	2016-05-19
CY1116247T1 (el)	2017-02-08
CY2016036I2 (el)	2017-07-12
PL2641601T3 (pl)	2017-01-31

Publication	Publication Date	Title
HUS1600043I1 (hu)	2016-12-28	Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
IL304150A (en)	2023-09-01	Antibodies against 38cd for the treatment of multiple myeloma
IL193920A0 (en)	2011-08-01	Methods of treating lupus using cd4 antibodies
EP2037961A4 (en)	2010-06-30	METHODS OF TREATING AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY
IL194776A0 (en)	2009-08-03	Humanized c-kit antibody
IL196920A0 (en)	2011-08-01	Compositions and methods using anti-csi antibodies to treat multiple myeloma
EP1998807A4 (en)	2010-02-17	METHODS OF HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES THUS OBTAINED
SI2029155T1 (sl)	2016-06-30	Izboljšano zdravljenje multiplega mieloma
IL243687A0 (en)	2016-04-21	For the treatment of multiple myeloma 1–cs antibodies against
ZA200807524B (en)	2009-10-28	Methods of treating lupus using CD4 antibodies
SI2068930T1 (sl)	2013-01-31	Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
IL194373A0 (en)	2011-08-01	Methods for treating kidney disorders
ZA200903242B (en)	2010-08-25	Treatment for multiple myeloma
HUS1700054I1 (hu)	2018-06-28	CD38-ellenes antitestek a mielóma multiplex kezelésére
SG10201610317VA (en)	2017-02-27	Antibodies against cd38 for treatment of multiple myeloma